[go: up one dir, main page]

MX2023013683A - Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). - Google Patents

Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).

Info

Publication number
MX2023013683A
MX2023013683A MX2023013683A MX2023013683A MX2023013683A MX 2023013683 A MX2023013683 A MX 2023013683A MX 2023013683 A MX2023013683 A MX 2023013683A MX 2023013683 A MX2023013683 A MX 2023013683A MX 2023013683 A MX2023013683 A MX 2023013683A
Authority
MX
Mexico
Prior art keywords
kat6a
compounds
inhibitors
fused
isoxazolil
Prior art date
Application number
MX2023013683A
Other languages
English (en)
Inventor
Chandrasekhar Abbineni
Susanta Samajdar
Chandregowda Venkateshappa
Kalisankar Bera
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of MX2023013683A publication Critical patent/MX2023013683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de isoxazolilo fusionados de fórmula (I), que son terapéuticamente útiles como inhibidores de KAT6A particularmente en el tratamiento y/o prevención de enfermedades o trastornos dependientes de KAT6A en un mamífero. La presente invención también proporciona la preparación de compuestos y composiciones farmacéuticas que comprenden al menos uno de los compuestos representados por la fórmula (I) o una sal farmacéuticamente aceptable o un estereoisómero o un tautómero de este.
MX2023013683A 2021-05-21 2022-05-21 Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). MX2023013683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141022736 2021-05-21
PCT/IB2022/054771 WO2022243983A1 (en) 2021-05-21 2022-05-21 Fused isoxazolyl compounds as kat6a inhibitors

Publications (1)

Publication Number Publication Date
MX2023013683A true MX2023013683A (es) 2024-02-23

Family

ID=84140350

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013683A MX2023013683A (es) 2021-05-21 2022-05-21 Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).

Country Status (10)

Country Link
US (1) US20240254139A1 (es)
EP (1) EP4341259A4 (es)
JP (1) JP2024521141A (es)
KR (1) KR20240012434A (es)
CN (1) CN117881677A (es)
AU (1) AU2022278733A1 (es)
CA (1) CA3221048A1 (es)
IL (1) IL308667A (es)
MX (1) MX2023013683A (es)
WO (1) WO2022243983A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20241355A1 (es) 2021-11-16 2024-07-03 Insilico Medicine Ip Ltd Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos
AU2023241822A1 (en) 2022-03-28 2024-09-26 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AU2024236161A1 (en) 2023-03-16 2025-08-21 Aurigene Oncology Limited Acylsulfonamide kat6a inhibitors
CN120957999A (zh) * 2023-03-27 2025-11-14 北京康辰药业股份有限公司 磺酰胺化合物、其药物组合物和应用
AR132470A1 (es) * 2023-04-19 2025-07-02 Insilico Medicine Ip Ltd Inhibidor de lisina-acetiltransferasa 6a (kat6a), combinaciones y usos del mismo
US20250122183A1 (en) * 2023-10-02 2025-04-17 Pfizer Inc. Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
PL4299135T3 (pl) * 2019-06-18 2025-11-12 Pfizer Inc. Pochodne benzizoksazolosulfonamidu

Also Published As

Publication number Publication date
KR20240012434A (ko) 2024-01-29
WO2022243983A1 (en) 2022-11-24
US20240254139A1 (en) 2024-08-01
CA3221048A1 (en) 2022-11-24
JP2024521141A (ja) 2024-05-28
EP4341259A4 (en) 2025-05-28
IL308667A (en) 2024-01-01
EP4341259A1 (en) 2024-03-27
CN117881677A (zh) 2024-04-12
AU2022278733A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2023007192A (es) Inhibidores de prmt5.
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
CY1124243T1 (el) Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
ATE517882T1 (de) Chinolinderivate
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2021011081A (es) Derivados de nicorandil.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
ATE540038T1 (de) Heterocyclen als proteinkinaseinhibitoren
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
EA202192760A1 (ru) Трициклические соединения
EA202190316A1 (ru) Конденсированное производное лактама
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
WO2020023340A8 (en) Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof
MX2024006176A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno.
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases